GEDEA BIOTECH AB

Their core work

GEDEA Biotech is a Swedish biotech SME developing a non-antibiotic treatment for recurrent vaginal infections — specifically designed to address both vaginal thrush (Candida) and bacterial vaginosis (Gardnerella) simultaneously, which current market products cannot do. Their product is a pessary formulation that works by restoring healthy vaginal microflora through lactobacilli rather than killing pathogens, bypassing the antimicrobial resistance problem entirely. The treatment is designed for over-the-counter self-use, meaning they are targeting the pharmacy and consumer health market rather than prescription channels. Their core value is a dual-action, resistance-free solution to a problem that affects millions of women and is poorly served by existing products.

What they specialise in

How they've shifted over time

GEDEA's H2020 trajectory follows a classic SME Instrument two-phase path: a 2018–2019 feasibility study (SME-1, €50K) with no detailed keywords, followed by a full innovation action (2020–2022, €2M) where the entire product concept crystallized into specific terms — candida, gardnerella, pessary, lactobacilli, self-treatment, AMR. This is not a pivot or a shift; it is a deepening of a single focused thesis from feasibility to clinical/market development. The absence of early-period keywords reflects the exploratory nature of phase one, not a different research direction. Their trajectory is entirely coherent: one problem, one product concept, two funding phases.

GEDEA is deep in late-stage product development for a specific OTC vaginal health product; a future collaborator would most likely be a clinical CRO, a pharmaceutical distributor, a women's health company, or a regulatory affairs partner for EU market entry.

How they like to work

GEDEA coordinates both of their projects — they are not passive consortium participants but the driving force behind the research agenda. Their consortia are small and targeted (6 unique partners across 5 countries), consistent with an SME-led innovation project where the company owns the IP and brings in specialist partners for specific tasks rather than building a broad academic network. Working with them means working under their product vision and commercial roadmap.

GEDEA has built a compact international network of 6 consortium partners across 5 countries, typical for a product-focused SME using EU funding to assemble the clinical, scientific, and regulatory expertise it cannot maintain in-house. The geographic spread suggests deliberate selection of specialist partners rather than proximity-based choices.

What sets them apart

GEDEA occupies a very specific niche: a dual-indication, non-antibiotic, OTC vaginal health product — a combination that no mainstream pharmaceutical product currently offers. Their differentiation is not just scientific but commercial: they are building toward a consumer health product, not a prescription drug, which means faster time-to-market and a different competitive landscape. For a consortium or business partner, GEDEA brings proprietary product IP, a clear AMR narrative for regulatory and funding purposes, and a women's health focus that is increasingly prioritized in EU health policy.

Highlights from their portfolio

• NEFERTITI (IA phase)
  With €2.05M in EC funding, this is the full innovation action bringing a dual-action vaginal microbiome pessary from concept to market-ready product — the largest single bet this SME has made and the clearest signal of their commercial intent.
• NEFERTITI (SME-1 phase)
  The €50K feasibility study that preceded the full IA demonstrates a disciplined two-phase EU funding strategy, validating the concept before scaling investment.